Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease.

Autor: Carlsen A; Stavanger University Hospital, PO Box 8100, 4068 Stavanger, Norway., Omdal R; Unit of Clinical Immunology, Department of Medicine, Stavanger University Hospital, Stavanger, Norway., Leitao KØ; Unit of Gastroenterology, Department of Medicine, Stavanger University Hospital, Stavanger, Norway., Isaksen K; Unit of Gastroenterology, Department of Medicine, Stavanger University Hospital, Stavanger, Norway., Hetta AK; Unit of Gastroenterology, Department of Medicine, Stavanger University Hospital, Stavanger, Norway., Karlsen LN; Unit of Gastroenterology, Department of Medicine, Stavanger University Hospital, Stavanger, Norway., Aabakken L; Department of Gastroenterology, Oslo University Hospital, Oslo, Norway., Bolstad N; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Warren D; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Lundin KEA; Department of Gastroenterology, Oslo University Hospital, Oslo, Norway., Grimstad T; Unit of Gastroenterology, Department of Medicine, Stavanger University Hospital, Stavanger, Norway.

Publikováno v: Therapeutic advances in gastroenterology [Therap Adv Gastroenterol] 2018 Mar 14; Vol. 11, pp. 1756284818759930. Date of Electronic Publication: 2018 Mar 14 (Print Publication: 2018).